Eli Lilly and Peptron maintain an ongoing technology evaluation agreement focused on applying the SmartDepot long-acting peptide delivery platform to select Lilly candidates, but this remains in the research and feasibility stage rather than commercial licensing. The collaboration, initiated via a 2024 material transfer agreement and extended through late 2026, explicitly excludes high-profile assets such as tirzepatide-based products, while Lilly has pursued alternative sustained-release partnerships. With only weeks remaining before the October 7 resolution date and no public announcements of binding license, technology transfer, or equivalent commercial terms, traders assign an 84.5% implied probability to “No,” reflecting the extended evaluation timeline, limited scope, and absence of recent catalysts that would accelerate a deal.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-updateEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
16% tsansa
$11,264 Vol.
$11,264 Vol.
Oct 6, 2026
16% tsansa
$11,264 Vol.
$11,264 Vol.
Oct 6, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron maintain an ongoing technology evaluation agreement focused on applying the SmartDepot long-acting peptide delivery platform to select Lilly candidates, but this remains in the research and feasibility stage rather than commercial licensing. The collaboration, initiated via a 2024 material transfer agreement and extended through late 2026, explicitly excludes high-profile assets such as tirzepatide-based products, while Lilly has pursued alternative sustained-release partnerships. With only weeks remaining before the October 7 resolution date and no public announcements of binding license, technology transfer, or equivalent commercial terms, traders assign an 84.5% implied probability to “No,” reflecting the extended evaluation timeline, limited scope, and absence of recent catalysts that would accelerate a deal.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Binuksan ang Market: May 5, 2026, 8:02 PM ET
Volume
$11,264Petsa ng Pagtatapos
Oct 7, 2026Binuksan ang Market
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron maintain an ongoing technology evaluation agreement focused on applying the SmartDepot long-acting peptide delivery platform to select Lilly candidates, but this remains in the research and feasibility stage rather than commercial licensing. The collaboration, initiated via a 2024 material transfer agreement and extended through late 2026, explicitly excludes high-profile assets such as tirzepatide-based products, while Lilly has pursued alternative sustained-release partnerships. With only weeks remaining before the October 7 resolution date and no public announcements of binding license, technology transfer, or equivalent commercial terms, traders assign an 84.5% implied probability to “No,” reflecting the extended evaluation timeline, limited scope, and absence of recent catalysts that would accelerate a deal.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,264Petsa ng Pagtatapos
Oct 7, 2026Binuksan ang Market
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly and Peptron maintain an ongoing technology evaluation agreement focused on applying the SmartDepot long-acting peptide delivery platform to select Lilly candidates, but this remains in the research and feasibility stage rather than commercial licensing. The collaboration, initiated via a 2024 material transfer agreement and extended through late 2026, explicitly excludes high-profile assets such as tirzepatide-based products, while Lilly has pursued alternative sustained-release partnerships. With only weeks remaining before the October 7 resolution date and no public announcements of binding license, technology transfer, or equivalent commercial terms, traders assign an 84.5% implied probability to “No,” reflecting the extended evaluation timeline, limited scope, and absence of recent catalysts that would accelerate a deal.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong